Precision identification of mechanisms and markers of infectious and renal disease.
HSL underwent a major restructuring in 2016 when the configuration of the company was changed. New directors were recruited with the expertise required to develop a modern international company capable of expanding to meet the needs of our customers. We acquired product lines, such as Rapichrome™ NAG, which complimented our existing services and brought in the professionals who could support the new products and initiate an expanding research and development programme. Future products will be based on this strong R&D programme.